Indan-1-one O-methyl-oxime | 121696-18-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: Indan-1-one O-methyl-oxime
• 英文别名: (E)-N-methoxy-2,3-dihydroinden-1-imine
• CAS: 121696-18-2
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: KJEJJACMRHNNNZ-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氯苯甲酰乙腈 、 1-茚酮 生成 Indan-1-one O-methyl-oxime
  参考文献：
  名称：

  IRIE, HIROSHI;TANAKA, SHOKO;ZHANG, YONG;KOYAMA, JUNKO;TAGA, TOORU;MACHIDA+, CHEM. AND PHARM. BULL., 36,(1988) N 8, C. 3134-3137

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDES HÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR P2X7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014115072A1

  公开（公告）日：2014-07-31

  The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及式(I)的杂环酰胺衍生物，其中R1、R2、R3、R4、R5、n、m、p和X如描述中定义，及其制备方法和作为药物活性化合物用途。
• COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS
  申请人：Campbell David

  公开号：US20120046283A1

  公开（公告）日：2012-02-23

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of neuropsychiatric conditions.

  本文提供了PAK抑制剂及其在治疗神经精神疾病方面的应用方法。
• OXYIMINO COMPOUNDS AND THE USE THEREOF
  申请人：Masui Moriyasu

  公开号：US20100240703A1

  公开（公告）日：2010-09-23

  The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SO m ; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R 1 and R 2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl etc., each X is independently ═O, optionally substituted lower alkyl, cyano, nitro etc., m is 1 or 2, p is O, 1 or 2 and q is O or 1. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及公式I的氧亚胺化合物及其药学上可接受的盐、前药和溶剂化合物，其中：Y为CO或SOm；Z为氢、每个可选择的取代较低的烷基、较低的烯基、芳香基、杂环基等。R1和R2分别独立地为氢、每个可选择的取代较低的烷基、较低的烯基、环烷基、芳香基、杂环基等，每个X独立地为═O、可选择的取代较低的烷基、氰基、硝基等，m为1或2，p为O、1或2，q为O或1。本发明还涉及使用公式I的化合物来治疗、预防或缓解对钙通道阻滞有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• METHODS FOR TREATING SCHIZOPHRENIA
  申请人：Lichter Jay

  公开号：US20120184547A1

  公开（公告）日：2012-07-19

  Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from schizophrenia.

  提供PAK抑制剂。此外，还提供了用于治疗患有精神分裂症的个体的组合物和方法。
• PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：US20130252957A1

  公开（公告）日：2013-09-26

  The present invention provides compounds that are alpha4 integrin antagonists having a structure according to the following formula: or a tautomer, mixture of tautomers, salt or solvate thereof, wherein Cy, ring A, m, n, p, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined in the specification. The invention further provides pharmaceutical compositions including the compounds of the invention as well as methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various conditions and disorders, such as Crohn's disease and ulcerative colitis.

  本发明提供具有以下结构的α4整合素拮抗剂化合物：或其互变异构体，互变异构体混合物，盐或溶剂化物，其中Cy，环A，m，n，p，R1，R2，R3，R4，R5和R6在说明书中定义。本发明还提供包括本发明化合物的制药组合物，以及使用本发明化合物和组合物的方法，例如在治疗和预防各种疾病和障碍，如克罗恩病和溃疡性结肠炎中。